Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02032823 · OUTCOME

Change From Baseline for EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core Questions 30) Scores for Participants Who Completed Neoadjuvant Chemotherapy

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer · Source last updated 2026-07-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Scores on a scale
Interval / dispersion
95% Confidence Interval
Time frame
6, 12, 18 and 24 months after randomisation (data cut off: 12 July 2021)

What was measured

Change from baseline for EORTC QLQ-C30 Global health status QOL (Quality of Life) Score at 6, 12, 18 and 24 months for patients who completed neoadjuvant chemotherapy. Adjusted least-square mean changes and 95% CI are obtained from mixed model for repeated measures (MMRM) analysis of the change from baseline. Only patients with evaluable baseline forms are included. EORTC QLQ-C30 scores range from 0 to 100 with higher score indicating better quality of life.

Analysis population: Patient reported outcomes (PRO) Analysis Set

Groups in this outcome

Olaparib

Olaparib tablets 300mg taken orally twice daily.

Placebo

Placebo tablets taken orally twice daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Olaparib382
Placebo358

Reported measurements

Change from baseline EORTC QLQ-C30 Global health status score to 6 months
Values in Scores on a scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Olaparib-0.4Not reported-2.21.4Not reported
Placebo0.4Not reported-1.42.2Not reported
Change from baseline EORTC QLQ-C30 Global health status score to 12 months
Values in Scores on a scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Olaparib0.5Not reported-1.52.4Not reported
Placebo2.7Not reported0.74.7Not reported
Change from baseline EORTC QLQ-C30 Global health status score to 18 months
Values in Scores on a scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Olaparib3.3Not reported1.35.3Not reported
Placebo4.4Not reported2.36.4Not reported
Change from baseline EORTC QLQ-C30 Global health status score to 24 months
Values in Scores on a scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Olaparib2.8Not reported0.65.0Not reported
Placebo6.1Not reported3.88.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -2.2
        upper Limit
        1.4
        value
        -0.4
      2. group Id
        OG001
        lower Limit
        -1.4
        upper Limit
        2.2
        value
        0.4
    title
    Change from baseline EORTC QLQ-C30 Global health status score to 6 months
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -1.5
        upper Limit
        2.4
        value
        0.5
      2. group Id
        OG001
        lower Limit
        0.7
        upper Limit
        4.7
        value
        2.7
    title
    Change from baseline EORTC QLQ-C30 Global health status score to 12 months
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.3
        upper Limit
        5.3
        value
        3.3
      2. group Id
        OG001
        lower Limit
        2.3
        upper Limit
        6.4
        value
        4.4
    title
    Change from baseline EORTC QLQ-C30 Global health status score to 18 months
  4. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.6
        upper Limit
        5.0
        value
        2.8
      2. group Id
        OG001
        lower Limit
        3.8
        upper Limit
        8.4
        value
        6.1
    title
    Change from baseline EORTC QLQ-C30 Global health status score to 24 months
denoms
  1. counts
    1. group Id
      OG000
      value
      382
    2. group Id
      OG001
      value
      358
    units
    Participants
description
Change from baseline for EORTC QLQ-C30 Global health status QOL (Quality of Life) Score at 6, 12, 18 and 24 months for patients who completed neoadjuvant chemotherapy. Adjusted least-square mean changes and 95% CI are obtained from mixed model for repeated measures (MMRM) analysis of the change from baseline. Only patients with evaluable baseline forms are included. EORTC QLQ-C30 scores range from 0 to 100 with higher score indicating better quality of life.
dispersion Type
95% Confidence Interval
groups
  1. description
    Olaparib tablets 300mg taken orally twice daily.
    id
    OG000
    title
    Olaparib
  2. description
    Placebo tablets taken orally twice daily.
    id
    OG001
    title
    Placebo
param Type
MEAN
population Description
Patient reported outcomes (PRO) Analysis Set
reporting Status
POSTED
time Frame
6, 12, 18 and 24 months after randomisation (data cut off: 12 July 2021)
title
Change From Baseline for EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core Questions 30) Scores for Participants Who Completed Neoadjuvant Chemotherapy
type
SECONDARY
unit Of Measure
Scores on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice